MCID: ACT234
MIFTS: 25

Acute Myeloid Leukemia with Minimal Differentiation

Categories: Blood diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Acute Myeloid Leukemia with Minimal Differentiation

MalaCards integrated aliases for Acute Myeloid Leukemia with Minimal Differentiation:

Name: Acute Myeloid Leukemia with Minimal Differentiation 59
Minimally Differentiated Acute Myeloblastic Leukemia 59
Aml M0 59

Characteristics:

Orphanet epidemiological data:

59

Classifications:



External Ids:

Orphanet 59 ORPHA98832
UMLS via Orphanet 74 C0522631
ICD10 via Orphanet 34 C92.0

Summaries for Acute Myeloid Leukemia with Minimal Differentiation

MalaCards based summary : Acute Myeloid Leukemia with Minimal Differentiation, also known as minimally differentiated acute myeloblastic leukemia, is related to leukemia, acute myeloid and cervicitis. An important gene associated with Acute Myeloid Leukemia with Minimal Differentiation is FLT3 (Fms Related Tyrosine Kinase 3), and among its related pathways/superpathways are Endometrial cancer and Transcriptional misregulation in cancer. The drugs tipifarnib and Lenalidomide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Acute Myeloid Leukemia with Minimal Differentiation

Diseases related to Acute Myeloid Leukemia with Minimal Differentiation via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 13)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute myeloid 28.7 FLT3 MPO
2 cervicitis 10.1
3 leukemia 10.1
4 myeloid leukemia 10.1
5 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 9.6 FLT3 MPO
6 aleukemic leukemia cutis 9.6 FLT3 MPO
7 myeloid sarcoma 9.6 FLT3 MPO
8 leukemia, acute lymphoblastic 3 9.6 FLT3 MPO
9 precursor t-cell acute lymphoblastic leukemia 9.5 FLT3 MPO
10 acute leukemia 9.5 FLT3 MPO
11 bone marrow cancer 9.4 FLT3 MPO
12 leukemia, chronic myeloid 9.3 FLT3 MPO
13 acute promyelocytic leukemia 9.2 FLT3 MPO

Graphical network of the top 20 diseases related to Acute Myeloid Leukemia with Minimal Differentiation:



Diseases related to Acute Myeloid Leukemia with Minimal Differentiation

Symptoms & Phenotypes for Acute Myeloid Leukemia with Minimal Differentiation

GenomeRNAi Phenotypes related to Acute Myeloid Leukemia with Minimal Differentiation according to GeneCards Suite gene sharing:

26 (show all 19)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.62 MPO
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.62 FLT3
3 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.62 FLT3
4 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.62 FLT3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.62 FLT3
6 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.62 FLT3
7 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.62 FLT3
8 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.62 FLT3
9 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.62 MPO
10 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.62 MPO
11 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.62 FLT3
12 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.62 MPO
13 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.62 MPO
14 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.62 FLT3
15 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.62 MPO
16 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.62 MPO
17 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.62 MPO
18 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.62 MPO
19 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.62 MPO FLT3

Drugs & Therapeutics for Acute Myeloid Leukemia with Minimal Differentiation

Drugs for Acute Myeloid Leukemia with Minimal Differentiation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 56)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
tipifarnib Investigational Phase 3,Phase 2,Phase 1 192185-72-1 159324
2
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
3
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
4
Vidarabine Approved, Investigational Phase 2 24356-66-9 32326 21704
5
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
6
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
7
Busulfan Approved, Investigational Phase 2 55-98-1 2478
8
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
9
Azacitidine Approved, Investigational Phase 2,Phase 1 320-67-2 9444
10
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 59-30-3 6037
11
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006
12 Angiogenesis Inhibitors Phase 1, Phase 2
13 Angiogenesis Modulating Agents Phase 1, Phase 2
14 Anti-Bacterial Agents Phase 1, Phase 2
15 Immunosuppressive Agents Phase 1, Phase 2,Phase 2
16 Anti-Infective Agents Phase 1, Phase 2,Phase 2
17 Vitamin B Complex Phase 2,Phase 1
18 Antimetabolites Phase 2,Phase 1
19 Antiviral Agents Phase 2
20 Antimetabolites, Antineoplastic Phase 2,Phase 1
21 Alkylating Agents Phase 2
22 Folic Acid Antagonists Phase 2
23 Dermatologic Agents Phase 2,Phase 1
24 Nucleic Acid Synthesis Inhibitors Phase 2
25 Vidarabine Phosphate Phase 2
26 Antilymphocyte Serum Phase 2
27 Antirheumatic Agents Phase 2
28 Calcineurin Inhibitors Phase 2
29 Antineoplastic Agents, Alkylating Phase 2
30 Folate Nutraceutical Phase 2,Phase 1
31 Vitamin B9 Nutraceutical Phase 2,Phase 1
32
Sorafenib Approved, Investigational Phase 1 284461-73-0 216239 406563
33
Bortezomib Approved, Investigational Phase 1 179324-69-7 387447 93860
34
Carboplatin Approved Phase 1 41575-94-4 10339178 498142 38904
35
Topotecan Approved, Investigational Phase 1 119413-54-6, 123948-87-8 60700
36
Etoposide Approved Phase 1 33419-42-0 36462
37
Mitoxantrone Approved, Investigational Phase 1 65271-80-9 4212
38
Nicotinamide Approved, Investigational, Nutraceutical Phase 1 98-92-0 936
39
Niacin Approved, Investigational, Nutraceutical Phase 1 59-67-6 938
40
Veliparib Investigational Phase 1 912444-00-9 11960529
41 Micronutrients Phase 1
42 Nicotinic Acids Phase 1
43 Trace Elements Phase 1
44 Vitamins Phase 1
45 Protein Kinase Inhibitors Phase 1
46 topoisomerase I inhibitors Phase 1
47 Topoisomerase Inhibitors Phase 1
48 Poly(ADP-ribose) Polymerase Inhibitors Phase 1
49 Podophyllotoxin Phase 1 518-28-5
50 Analgesics Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission Completed NCT00093470 Phase 3 Tipifarnib
2 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant Unknown status NCT02038153 Phase 1, Phase 2 Lenalidomide
3 Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia Completed NCT01870596 Phase 2 Cytarabine;CHK1 Inhibitor SCH 900776
4 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Completed NCT01361464 Phase 2 Tipifarnib
5 Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia Active, not recruiting NCT01168219 Phase 2 Azacitidine;Busulfan;Fludarabine Phosphate;Methotrexate;Tacrolimus
6 Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase Completed NCT00383474 Phase 1 Bortezomib;Tipifarnib
7 Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia Completed NCT00217646 Phase 1 Sorafenib Tosylate
8 Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders Active, not recruiting NCT00588991 Phase 1 Carboplatin;Topotecan Hydrochloride;Veliparib
9 Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia Terminated NCT01260714 Phase 1 Azacitidine;Etoposide;Mitoxantrone Hydrochloride

Search NIH Clinical Center for Acute Myeloid Leukemia with Minimal Differentiation

Genetic Tests for Acute Myeloid Leukemia with Minimal Differentiation

Anatomical Context for Acute Myeloid Leukemia with Minimal Differentiation

MalaCards organs/tissues related to Acute Myeloid Leukemia with Minimal Differentiation:

41
Myeloid

Publications for Acute Myeloid Leukemia with Minimal Differentiation

Articles related to Acute Myeloid Leukemia with Minimal Differentiation:

# Title Authors Year
1
TdT expression in acute myeloid leukemia with minimal differentiation is associated with distinctive clinicopathological features and better overall survival following stem cell transplantation. ( 22936064 )
2013
2
Acute myeloid leukemia with minimal differentiation: unusual cytogenetics, morphology, phenotype and clinical course. ( 22483069 )
2012
3
Acute myeloid leukemia with minimal differentiation. A multiple parameter study. ( 9426515 )
1998

Variations for Acute Myeloid Leukemia with Minimal Differentiation

Expression for Acute Myeloid Leukemia with Minimal Differentiation

Search GEO for disease gene expression data for Acute Myeloid Leukemia with Minimal Differentiation.

Pathways for Acute Myeloid Leukemia with Minimal Differentiation

Pathways related to Acute Myeloid Leukemia with Minimal Differentiation according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.9 FLT3 MPO
2 11.23 FLT3 MPO
3 10.69 FLT3 MPO

GO Terms for Acute Myeloid Leukemia with Minimal Differentiation

Biological processes related to Acute Myeloid Leukemia with Minimal Differentiation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 8.62 FLT3 MPO

Sources for Acute Myeloid Leukemia with Minimal Differentiation

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....